NASDAQ:CVAC CureVac (CVAC) Stock Price, News & Analysis $4.66 0.00 (0.00%) As of 10/20/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About CureVac Stock (NASDAQ:CVAC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CureVac alerts:Sign Up Key Stats Today's Range$4.66▼$4.6650-Day Range$4.66▼$4.6652-Week Range$3.13▼$5.72VolumeN/AAverage Volume992,546 shsMarket Capitalization$1.05 billionP/E Ratio6.47Dividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview CureVac N.V. is a biotechnology company focused on developing messenger RNA (mRNA)-based medicines and vaccines. Its research uses mRNA molecules to instruct cells to produce therapeutic proteins or disease-targeting antigens, with the goal of treating or preventing infectious diseases, cancer and other medical conditions. The company’s development programs have included prophylactic vaccines for infectious diseases, therapeutic cancer vaccines and treatments designed to stimulate the immune system. CureVac has also developed mRNA manufacturing and delivery technologies intended to improve the stability, performance and scalability of mRNA-based products. Founded in 2000 and headquartered in Tübingen, Germany, CureVac has operated internationally through research, clinical development and commercial collaborations. The company became publicly traded in the United States in 2020 through American Depositary Shares listed on the Nasdaq under the symbol CVAC. Its programs and partnerships have involved pharmaceutical and biotechnology organizations in Europe, North America and other global markets.AI Generated. May Contain Errors. Read More Receive CVAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CVAC Stock News HeadlinesCureVac sues Moderna for patent infringement over COVID-19 vaccinesApril 24, 2026 | reuters.comCureVac (NasdaqGM:CVAC) Valuation After New mRNA Pipeline Progress And Refined Capital Allocation PlanJanuary 22, 2026 | finance.yahoo.comYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strategy guide, titled How To Turn 100 Into 1000 Gains, before it moves behind a paywall. The guide walks through options trading concepts the team uses in its own research and education materials. Once the paywall goes up, free access ends for good.October 22 at 1:00 AM | TradeWins (Ad)BioNTech Completes CureVac Takeover and Updates Articles of AssociationJanuary 6, 2026 | tipranks.comBioNTech SE (BNTX) Closes the Acquisition of CureVac N.V.December 23, 2025 | insidermonkey.comBioNTech Completes CureVac Acquisition to Bolster mRNA LeadershipDecember 18, 2025 | tipranks.comCureVac NV (CVAC): A bull case theoryDecember 4, 2025 | msn.comBioNTech Achieves Minimum Condition in CureVac Exchange OfferDecember 3, 2025 | globenewswire.comSee More Headlines CVAC Stock Analysis - Frequently Asked Questions How have CVAC shares performed this year? CureVac's stock was trading at $4.52 at the beginning of 2026. Since then, CVAC stock has increased by 3.1% and is now trading at $4.66. How were CureVac's earnings last quarter? CureVac N.V. (NASDAQ:CVAC) released its earnings results on Monday, November, 24th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.07. The company had revenue of $63.53 million for the quarter, compared to analyst estimates of $21.40 million. CureVac had a negative trailing twelve-month return on equity of 23.03% and a net margin of 199.92%. When did CureVac IPO? CureVac (CVAC) raised $200 million in an initial public offering on Friday, August 14th 2020. The company issued 13,333,333 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers. How do I buy shares of CureVac? Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CureVac own? Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include Tesla (TSLA), Novavax (NVAX), Moderna (MRNA), NIO (NIO), BioNTech (BNTX), NVIDIA (NVDA) and Pfizer (PFE). Company Calendar Last Earnings11/24/2025Today10/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (16m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CVAC's financial health is in the Green zone, according to TradeSmith. CVAC has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CVAC CIK1809122 Webwww.curevac.com Phone49-70-71988-30Fax49-7071-9883Employees880Year Founded2000Profitability EPS (Trailing Twelve Months)$0.72 Trailing P/E Ratio6.47 Forward P/E Ratio6.47 P/E GrowthN/ANet Income$175.50 million Net Margins199.92% Pretax Margin232.79% Return on Equity-23.03% Return on Assets-19.09% Debt Debt-to-Equity Ratio0.03 Current Ratio3.70 Quick Ratio3.69 Sales & Book Value Annual Sales$70.74 million Price / Sales14.78 Cash Flow$0.99 per share Price / Cash Flow4.73 Book Value$3.36 per share Price / Book1.39Miscellaneous Outstanding Shares224,338,000Free Float219,515,000Market Cap$1.05 billion OptionableNo Data Beta1.77 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:CVAC) was last updated on 10/20/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
